Simon TG - Search Results

1

Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.

Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, Miller KK, Hoshida Y, Corey KE, Loomba R, Chung RT, Chan AT. Simon TG, et al. JAMA. 2024 Mar 19;331(11):920-929. doi: 10.1001/jama.2024.1215. JAMA. 2024. PMID: 38502074 Free PMC article. Clinical Trial.

2

Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.

Simon TG, King LY, Zheng H, Chung RT. Simon TG, et al. J Hepatol. 2015 Jan;62(1):18-23. doi: 10.1016/j.jhep.2014.08.013. Epub 2014 Aug 15. J Hepatol. 2015. PMID: 25135867 Free PMC article. Clinical Trial.

3

Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes.

Johnson KB, Mueller JL, Simon TG, Zheng H, King LY, Makar RS, Gervais DA, Chung RT. Johnson KB, et al. Among authors: simon tg. Dig Dis Sci. 2015 Jul;60(7):2190-5. doi: 10.1007/s10620-015-3578-z. Epub 2015 Feb 28. Dig Dis Sci. 2015. PMID: 25724164

4

Reply to: "Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis".

Simon TG, King LY, Chung RT. Simon TG, et al. J Hepatol. 2015 Jul;63(1):279. doi: 10.1016/j.jhep.2015.02.028. Epub 2015 Feb 26. J Hepatol. 2015. PMID: 25728638 Free article. No abstract available.

5

Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.

Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung RT, Rogal SS; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Butt AA, et al. Among authors: simon tg. Hepatology. 2015 Aug;62(2):365-74. doi: 10.1002/hep.27835. Epub 2015 May 23. Hepatology. 2015. PMID: 25847403

6

The new hepatitis C virus bottleneck: Can delaying therapy be justified?

Simon TG, Chung RT. Simon TG, et al. Hepatology. 2015 Sep;62(3):666-7. doi: 10.1002/hep.27931. Epub 2015 Jul 14. Hepatology. 2015. PMID: 26058922 No abstract available.

7

Reply.

Simon TG, Chung RT. Simon TG, et al. Hepatology. 2016 Jun;63(6):2066-7. doi: 10.1002/hep.28136. Epub 2015 Nov 26. Hepatology. 2016. PMID: 26316092 No abstract available.

8

The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.

Simon TG, Kim AY, Stamm LM, Liu L, Mo H, Doehle B, Pang PS, Brainard DM, McHutchison JG, Gustafson J, Lauer GM, Chung RT. Simon TG, et al. Antivir Ther. 2016;21(3):185-94. doi: 10.3851/IMP2997. Epub 2015 Oct 6. Antivir Ther. 2016. PMID: 26440471

9

Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES.

Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB; ERCHIVES study team. Butt AA, et al. Among authors: simon tg. BMC Infect Dis. 2015 Nov 11;15:510. doi: 10.1186/s12879-015-1268-2. BMC Infect Dis. 2015. PMID: 26558512 Free PMC article.

10

Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.

Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Simon TG, et al. Hepatology. 2016 Jul;64(1):47-57. doi: 10.1002/hep.28506. Epub 2016 Mar 25. Hepatology. 2016. PMID: 26891205 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters